{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:38:14Z","timestamp":1791632294764,"version":"4.3.4"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004699","name":"Chung Shan Medical University Hospital","doi-asserted-by":"publisher","award":["CSH-2022-A-022"],"award-info":[{"award-number":["CSH-2022-A-022"]}],"id":[{"id":"10.13039\/501100004699","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Individuals with bipolar disorder face a significantly elevated suicide risk, and comorbid type 2 diabetes mellitus (T2DM) further complicates their psychiatric and medical outcomes. Sodium\u2013glucose co-transporter-2 inhibitors (SGLT-2i) have demonstrated cardiometabolic benefits in T2DM, but their impact on psychiatric outcomes remains unclear. This study investigates whether SGLT-2i use is associated with a lower risk of suicide-related events compared to dipeptidyl peptidase-4 inhibitors (DPP-4i) in individuals with bipolar disorder and T2DM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective cohort study using the TriNetX US Collaborative Network, a large electronic health record database. Patients were included if they had bipolar disorder, were receiving active psychiatric treatment, and initiated either SGLT-2i or DPP-4i between 1 January 2015, and 30 June 2024. The primary outcome was the occurrence of suicide-related events, including suicidal ideation, suicide attempt, or intentional self-harm. Secondary outcomes included all-cause mortality, end-stage renal disease (ESRD), diabetic ketoacidosis (DKA), acute kidney injury (AKI), sepsis, genital infections, urinary tract infections (UTIs), and lower-limb amputation. Propensity score matching (1:1) was used to balance baseline characteristics. Cox proportional hazards models estimated hazard ratios (HRs) with 95% confidence intervals (CIs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The matched cohort included 1,711 patients per group (SGLT-2i vs. DPP-4i). Over a median follow-up of 887 vs. 797\u00a0days, suicide-related events occurred in 5.1% of SGLT-2i users vs. 7.3% of DPP-4i users (HR: 0.660, 95% CI: 0.473\u20130.921, p = 0.0145). All-cause mortality was also lower in the SGLT-2i group (HR: 0.594, 95% CI: 0.451\u20130.783, p &amp;lt; 0.001). No significant increase in adverse events such as DKA or infections was observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this real-world cohort study, SGLT-2i use was associated with a significantly lower risk of suicide-related events and all-cause mortality compared to DPP-4i in individuals with bipolar disorder and T2DM. Subgroup analyses stratified by age, sex, race, glycemic control (HbA1c), kidney function (eGFR), and baseline lithium use revealed no evidence of increased suicide risk in any subgroup. These findings suggest that SGLT-2 inhibitors may have a neutral to potentially protective effect on suicide-related outcomes. Further prospective studies are warranted to confirm these observations and explore the underlying mechanisms.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1601118","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T12:11:51Z","timestamp":1749643911000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Association between SGLT-2 inhibitors and suicide risk in type 2 diabetes and bipolar: a real-world cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"En-Wei","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Yang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Chang","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Ning","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Sun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edy","family":"Kornelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0000000000001001","article-title":"Risk of depression and dementia among individuals treated with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists","author":"Almeida","year":"2025","journal-title":"Curr. Opin. Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jad.2008.04.013","article-title":"Oxidative stress markers in bipolar disorder: a meta-analysis","volume":"111","author":"Andreazza","year":"2008","journal-title":"J. Affect. Disord."},{"key":"B3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00441-008-0685-6","article-title":"Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity","volume":"335","author":"Bakker","year":"2009","journal-title":"Cell Tissue Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejpsy.2021.11.002","article-title":"Bipolar disorder and type 2 diabetes mellitus: a bidirectional relationship","volume":"36","author":"Breznoscakova","year":"2022","journal-title":"Eur. J. Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3109\/07853890.2012.687835","article-title":"The relationship between bipolar disorder and type 2 diabetes: more than just co-morbid disorders","volume":"45","author":"Calkin","year":"2013","journal-title":"Ann. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1152\/physiol.00047.2018","article-title":"Central and peripheral inflammation link metabolic syndrome and major depressive disorder","volume":"34","author":"Chan","year":"2019","journal-title":"Physiol. (Bethesda)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"B8","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/00008877-200609000-00009","article-title":"Neuroprotective and disease-modifying effects of the ketogenic diet","volume":"17","author":"Gasior","year":"2006","journal-title":"Behav. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"E1161","DOI":"10.1152\/ajpendo.1995.268.6.E1161","article-title":"Blood-brain barrier permeability of glucose and ketone bodies during short-term starvation in humans","volume":"268","author":"Hasselbalch","year":"1995","journal-title":"Am. J. Physiology-Endocrinol. Metab."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.3390\/cells11193107","article-title":"Anti-inflammatory properties of the SGLT2 inhibitor empagliflozin in activated primary microglia","volume":"11","author":"Heimke","year":"2022","journal-title":"Cells"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00228-023-03539-8","article-title":"Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014\u20132022)","volume":"79","author":"Lin","year":"2023","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.brainresrev.2008.09.002","article-title":"The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies","volume":"59","author":"Maalouf","year":"2009","journal-title":"Brain Res. Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"7213","DOI":"10.3390\/molecules26237213","article-title":"Neuroprotective effect of SGLT2 inhibitors","volume":"26","author":"Pawlos","year":"2021","journal-title":"Molecules"},{"key":"B15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.31887\/DCNS.2018.20.1\/bpenninx","article-title":"Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications","volume":"20","author":"Penninx","year":"2018","journal-title":"Dialogues Clin. Neurosci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"20406223221086996","DOI":"10.1177\/20406223221086996","article-title":"Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review","volume":"13","author":"Tharmaraja","year":"2022","journal-title":"Ther. Adv. Chronic Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/eip.13260","article-title":"Identifying pathways to early\u2010onset metabolic dysfunction, insulin resistance and inflammation in young adult inpatients with emerging affective and major mood disorders","volume":"16","author":"Tickell","year":"2022","journal-title":"Early Interv. Psych."},{"key":"B18","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2165\/00023210-200317070-00003","article-title":"Suicidal behaviour in bipolar disorder: risk and prevention","volume":"17","author":"Tondo","year":"2003","journal-title":"CNS Drugs"},{"key":"B19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3892\/etm.2023.11824","article-title":"Impact of SGLT2 inhibitors on metabolic status in patients with psychiatric disorders undergoing treatment with second\u2011generation antipsychotics (Review)","volume":"25","author":"Vasiliu","year":"2023","journal-title":"Exp. Ther. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12888-024-05627-0","article-title":"Efficacy of empagliflozin as adjunctive therapy to citalopram in major depressive disorder: a randomized double-blind, placebo-controlled clinical trial","volume":"24","author":"Zandifar","year":"2024","journal-title":"BMC Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1601118\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T12:11:52Z","timestamp":1749643912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1601118\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":22,"alternative-id":["10.3389\/fphar.2025.1601118"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1601118","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,11]]},"article-number":"1601118"}}